(R)-3-Benzyl-2,3,5-trihydro-1H, 4H-1,4-benzodiazepine-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (R)-3-Benzyl-2,3,5-trihydro-1H, 4H-1,4-benzodiazepine-2,5-dione
• 英文别名: (3R)-3-benzyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: IOYQGXYNQRRATP-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氯-3,1-苯并噁嗪-2,4-二酮 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 溶剂黄146 为溶剂， 生成 (R)-3-Benzyl-2,3,5-trihydro-1H, 4H-1,4-benzodiazepine-2,5-dione
  参考文献：
  名称：

  Glycine receptor antagonist pharmacophore

  摘要：

  通过向需要此类治疗的动物投药，揭示了治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥和诱导麻醉的方法是通过给予具有高结合到甘氨酸受体的化合物。

  公开号：

  US05597922A1

文献信息

• Identification of the benzodiazepines as a new class of antileishmanial agent
  作者：Rachel L. Clark、Katharine C. Carter、Alexander B. Mullen、Geoffrey D. Coxon、George Owusu-Dapaah、Emma McFarlane、M. Dao Duong Thi、M. Helen Grant、Justice N.A. Tettey、Simon P. Mackay

  DOI：10.1016/j.bmcl.2006.11.004

  日期：2007.2

  The continual increase in drug resistance; the lack of new chemotherapeutic agents; the toxicity of existing agents and the increasing morbidity with HIV co-infection mean the search for new antileishmanial agents has never been more urgent. We have identified the benzodiazepines as a structural class for antileishmanial hit optimisation, and demonstrated that their in vitro activity is comparable with the clinically used drug, sodium stibogluconate, and that the compounds are not toxic to macrophages. (c) 2006 Elsevier Ltd. All rights reserved.
• [EN] GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE<br/>[FR] PHARMACOPHORE D'ANTAGONISTES DU RECEPTEUR DE LA GLYCINE
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON

  公开号：WO1996004288A1

  公开（公告）日：1996-02-15

  (EN) Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotropic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a compound which has high binding to the glycine receptor.(FR) L'invention se rapporte à des procédés de traitement ou de prévention de la perte neuronale associée à l'attaque, à l'ischémie, aux traumatismes du SNC (système nerveux central), à l'hypoglycémie et aux interventions chirurgicales, ainsi qu'au traitement des maladies dégénératives telles que la maladie d'Alzheimer, la sclérose latérale amyotrophique, la maladie de Huntington et le syndrome de Down, et au traitement ou à la prévention des conséquences fâcheuses de l'hyperactivité des acides aminés excitateurs, et au traitement de l'anxiété, de la douleur chronique, des convulsions et à l'induction d'une anesthésie. Ces procédés consistent à administrer à un animal nécessitant ce type de traitement un composé qui se lie fortement au récepteur de la glycine.